Scientists use yellow fever vaccine to map immune System's battle plan
NCT ID NCT00694655
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gave 239 healthy adults the yellow fever vaccine to learn how the immune system fights viral infections. Researchers measured the strength and quality of T cell responses over up to one year. The goal was to understand immune reactions, not to test the vaccine itself, which is already approved and safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
239 people
The number who actually took part.
- Started
-
May 2008
- Finished
-
Aug 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Able to understand and give informed consent 2. Age 18-45 years 3. Participant agrees not to take any live vaccines 30 days before or after (14 days for inactivated, including coronavirus disease 2019 (COVID-19) vaccination) yellow fever vaccination 4. Women of child bearing potential must agree to use effective birth control throughout the duration of the study. A negative urine pregnancy test must be documented prior to vaccination. Participants who have a history of surgical sterilization or post-menopausal status \>1 year, are not required to have a pregnancy test. Exclusion Criteria: 1. Prior receipt of a yellow fever vaccine 2. Lived in a country/area which is endemic for yellow fever 3. Travel to country/area which is endemic for yellow fever. Subject to investigator discretion 4. History of previous yellow fever, West Nile, Dengue, St. Louis encephalitis, Japanese encephalitis vaccination or infection 5. Any history of allergy to eggs, chicken or gelatin or to any previous vaccine 6. A history of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study 7. History of HIV infection 8. Active Hepatitis B or Hepatitis C infection 9. COVID-19 infection in the last 30 days. Symptoms of COVID-19 must be completely resolved before yellow fever vaccine receipt. 10. History of any chronic medical conditions that are considered progressive (ex, diabetes, heart disease, lung disease, liver disease, kidney disease, gastrointestinal diseases and uncontrolled hypertension). Use of systemic immunosuppressive medications (ex, prednisone) for 2 weeks or more in the past 3 months 11. History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial 12. Thymus gland problems (such as myasthenia gravis, DiGeorge syndrome, thymoma) or removal of thymus gland or history of autoimmune disorder 13. Recipient of a blood products or immune globulin product within 42 days of the vaccination visit. Participants who received COVID monoclonal antibodies (mAbs) for treatment are not excluded 14. Pregnant women and nursing mothers or women who are planning to become pregnant for the duration of the study 15. Any condition in the opinion of the investigator that would interfere with the proper conduct of the trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Yellow fever are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Hope Clinic of the Emory Vaccine Center
Decatur, Georgia, 30030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new yellow fever vaccine match the old one?
- New yellow fever vaccine shows promise in Mid-Stage trial
- New vaccines for yellow fever and rabies enter first human tests
- New yellow fever vaccine shows promise in early human trial
- 10,000 people tested: Cambodia's massive disease hunt begins
- New yellow fever vaccine shows promise in early safety trial